LianBio rises on clinical supply deal with AstraZeneca

LianBio

12/07/2023 19:36

** Shares of Asia-focused biopharma firm LianBio  LIAN.O 
rise 3.3% to $2.48
    ** Co signs a clinical supply agreement with AstraZeneca
 AZN.L  in China 
    ** Deal to evaluate safety and efficacy of BBP-398, in
combination with AstraZeneca's osimertinib for the treatment of
patients with non-small cell lung cancer  
    ** Adds that the planned multi-center early-stage trial to
evaluate the inhibitor combination is expected to begin in the
second half of 2023
    ** LianBio's stock has risen 51.83% YTD

 (Reporting by Sruthi Narasimha Chari in Bengaluru)
 ((Sruthinarasimha.chari@thomsonreuters.com))